Showing 8991-9000 of 10817 results for "".
- Rock Creek Pharmaceuticals Adds KOLs to Enhance Dermatological Disease Programhttps://practicaldermatology.com/news/rock-creek-pharmaceuticals-adds-kols-to-enhance-dermatological-disease-program/2458794/Rock Creek Pharmaceuticals, Inc., a clinical stage drug development company focused on the application of its lead compound being developed to treat chronic inflammatory conditions, has retained two Key Opinion Leaders (KOLs), each having renowned international expertise in dermatological d
- DermTech Announces New Websitehttps://practicaldermatology.com/news/dermtech-announces-new-website/2458796/DermTech, Inc., a privately held commercial stage molecular diagnostic company developing gene expression tests for skin cancer, announced the release of its new website (www.dermtech.com), designed to provide education and inf
- Pfizer and Allergan to Combinehttps://practicaldermatology.com/news/pfizer-and-allergan-to-combine/2458803/The boards of directors for Pfizer Inc. and Allergan plc have both unanimously approved, and the companies have entered into, a definitive merger agreement under which Pfizer will combine with Allergan in a stock transaction currently valued at $363.63 per Allergan share, for a total enterprise v
- AMA Calls for Ban on Direct to Consumer Advertising of Prescription Drugs and Medical Deviceshttps://practicaldermatology.com/news/ama-calls-for-ban-on-direct-to-consumer-advertising-of-prescription-drugs-and-medical-devices/2458806/Physicians at the Interim Meeting of the American Medical Association (AMA) adopted new policy aimed at driving solutions to make prescription drugs more affordable. Physicians cited concerns that a growing proliferation of ads is driving demand for expensive treatments despite the clinic
- Dermatologist Launches Website For Anti-MOC Campaignhttps://practicaldermatology.com/news/dermatologist-launches-website-for-anti-moc-campaign/2458817/Aimed at dermatologists who “believe that board certification should be a one time right of passage and that Maintenance of Certification (MOC) is an undue burden,” a new website from Las Vegas dermatologist H. L. Greenberg, MD encourages board certified dermatologists to si
- Lumenis Acquires Pollogen and Expands its Aesthetic Divisionhttps://practicaldermatology.com/news/lumenis-acquires-pollogen-and-expands-its-aesthetic-division/2458827/Lumenis Ltd. completed its acquisition of Pollogen Ltd., an Israeli-based medical aesthetic company that develops and manufactures advanced technologies with full-lines of clinically proven, non-invasive, anti-aging facial and body contouring treatment platforms for a spectrum of aesthetic applic
- RXi Pharmaceuticals Announces Positive Interim Results in Phase 2a Dermatology Program with RXI-109https://practicaldermatology.com/news/rxi-pharmaceuticals-announces-positive-interim-results-in-phase-2a-dermatology-program-with-rxi-109/2458844/RXi Pharmaceuticals Corporation shared results from a blinded panel and an Investigator review showing that incision sites treated with RXI-109 after scar revision surgery achieved better scores as compared to control incision sites in the same subjects, three months post scar revision surgery.</
- Aclaris Announces Pricing of Initial Public Offeringhttps://practicaldermatology.com/news/aclaris-announces-pricing-of-initial-public-offering/2458854/Aclaris Therapeutics, Inc. announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $11.00 per share. The shares, approved for listing on The NASDAQ Global Select Market, will be traded under the ticker symbol ACRS. All of the common
- Allergan Completes Acquisition of Kybella Maker Kytherahttps://practicaldermatology.com/news/allergan-completes-acquisition-of-kybella-maker-kythera/2458856/Allergan plc has successfully completed the acquisition of Kythera Biopharmaceuticals, Inc. Allergan acquired Kythera in an all-cash transaction valued at approximately $2.1 billion. The acquisition of Kythera adds Kybella® (deoxych
- Nivolumab Approved in Combination with Ipilimumabhttps://practicaldermatology.com/news/nivolumab-approved-in-combination-with-ipilimumab/2458859/The FDA has granted accelerated approval to nivolumab (Opdivo Injection, Bristol-Myers Squibb Company) in combination with ipilimumab for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma. The clinical trial that supported approval randomized (2:1) 142